Pd17-03 prostate cancer patients that opted for active surveillance while having a suspicious mri are at increased risk of needing treatment. results of the movember foundation’s global action plan prostate cancer active surveillance (gap3) consortium

You have accessJournal of UrologyProstate Cancer: Localized: Active Surveillance I (PD17)1 Sep 2021PD17-03 PROSTATE CANCER PATIENTS THAT OPTED FOR ACTIVE SURVEILLANCE WHILE HAVING A SUSPICIOUS MRI ARE AT INCREASED RISK OF NEEDING TREATMENT. RESULTS OF THE MOVEMBER FOUNDATION’S GLOBAL ACTION PLAN PROSTATE CANCER ACTIVE SURVEILLANCE (GAP3) CONSORTIUM Jonathan Olivier, Weiyu Li, Daan Nieboer, Jozien Helleman, Vincent Gnanapragasam, Mark Frydenberg, Takuma Kato, Peter Carroll, Todd M. Morgan, Riccardo Valdagni, Jose Rubio-Briones, Eric Hyndman, Grégoire Robert, Phillip Stricker, Ivo Schoots, Masoom Haider, Caroline Moore, Brian Denton, and Arnauld Villers Jonathan OlivierJonathan Olivier More articles by this author , Weiyu LiWeiyu Li More articles by this author , Daan NieboerDaan Nieboer More articles by this author , Jozien HellemanJozien Helleman More articles by this author , Vincent GnanapragasamVincent Gnanapragasam More articles by this author , Mark FrydenbergMark Frydenberg More articles by this author , Takuma KatoTakuma Kato More articles by this author , Peter CarrollPeter Carroll More articles by this author , Todd M. MorganTodd M. Morgan More articles by this author , Riccardo ValdagniRiccardo Valdagni More articles by this author , Jose Rubio-BrionesJose Rubio-Briones More articles by this author , Eric HyndmanEric Hyndman More articles by this author , Grégoire RobertGrégoire Robert More articles by this author , Phillip StrickerPhillip Stricker More articles by this author , Ivo SchootsIvo Schoots More articles by this author , Masoom HaiderMasoom Haider More articles by this author , Caroline MooreCaroline Moore More articles by this author , Brian DentonBrian Denton More articles by this author , and Arnauld VillersArnauld Villers More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000001999.03AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Inclusion criteria for active surveillance (AS) are low or intermediate risk prostate cancer. Few studies report the predictive value of the presence of a suspicious lesion at MRI at the time of inclusion. Objective: To evaluate percentage of patients needing active treatment stratified by presence or absence of suspicious lesion at baseline MRI. METHODS: Retrospective analysis of data from the multicentric AS GAP3 Consortium database. Inclusion criteria were men with grade groups (GG) 1 or GG2 prostate cancer combined with PSA<20 ng/ml. A subgroup of patients who had MRI at baseline and for which MRI results and targeted biopsies were used for AS eligibility was selected. Suspicious MRI was defined as MRI lesion PI-RADS/Likert >3 and for which targeted biopsies did not lead to reclassification. Outcome Measurements and Statistical Analysis: Primary outcome was treatment free-survival (FS). Secondary outcomes were histological GG progression free-survival and all men continuing active surveillance (discontinuation free survival). RESULTS: The study cohort included 2119 patients (1035 non-suspicious MRI and 1084 suspicious MRI men) with a median follow up of 23 months (12-43). For the whole cohort, Treatment-FS was 71% (95%CI: 69-74) at 3-years. At 3 and 5-years Treatment-FS was 80% (95%CI: 77–83) and 70% (95%CI: 66–74) for non-suspicious MRI and 63% (95%CI: 59–66) and 49% (95%CI: 44–54) for suspicious MRI patients, respectively. Active treatment (HR=2.00, p<0.001), grade progression (HR=1.88, p<0.001) and discontinuation of AS (HR=1.71, p<0.001) were significantly higher in suspicious MRI men than in non-suspicious MRI patients (figure 1). CONCLUSIONS: Men with a suspicious MRI at time of inclusion in AS are more likely to have active treatment, than men with a non-suspicious MRI. Source of Funding: None © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e285-e285 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Jonathan Olivier More articles by this author Weiyu Li More articles by this author Daan Nieboer More articles by this author Jozien Helleman More articles by this author Vincent Gnanapragasam More articles by this author Mark Frydenberg More articles by this author Takuma Kato More articles by this author Peter Carroll More articles by this author Todd M. Morgan More articles by this author Riccardo Valdagni More articles by this author Jose Rubio-Briones More articles by this author Eric Hyndman More articles by this author Grégoire Robert More articles by this author Phillip Stricker More articles by this author Ivo Schoots More articles by this author Masoom Haider More articles by this author Caroline Moore More articles by this author Brian Denton More articles by this author Arnauld Villers More articles by this author Expand All Advertisement PDF downloadLoading ...